FDA sets standard review for Gilead's idelalisib in NHL PMLiVE The marketing application in NHL was filed last September on the back of a single phase II trial in patients whose disease had progressed despite treatment with Roche and Biogen Idec's Rituxan (rituximab) or conventional chemotherapy. Idelalisib ... 3 Reasons to Buy Gilead Sciences, Inc. Standard Review for Gilead's Oncology Candidate - Analyst Blog Gilead's Idelalisib NDA accepted by US FDA for the treatment of refractory ... |
